Information mRNA & saRNA
Optimized and Stabilized mRNAs
OZ Biosciences offers mRNAs that mimic fully processed mature mRNAs. These mRNAs are stabilized with 5’ Cap 1 structure and 3’ poly(A) tail and are optimized to yield improved stability & performance. They are modified with 5-methoxyuridine (5moU replaces U) or N1-methyl-pseudouridine (N1-mψ) to reduce innate immune responses. We also offer unmodified mRNAs.
CAP1 is the best available enzymatic capping. It shows the same capping efficiency and transcription yield as the mRNA with a CleanCap® structure.
7 categories of ready-to-use mRNAs
- Reporter gene mRNAs: ideal controls to study transfection efficiency.
- Fluorescent mRNAs: F-Luc and GFP mRNA fluorescently labeled with Cy5, Cy3, or AlexaFluor488.
- Genome editing mRNAs: Cas9, CRE and Cas13d mRNA.
- Vaccine mRNAs: ideal as controls for immunization or vaccine studies.
- Gene Replacement mRNAs: EPO mRNA.
- Interleukin mRNA: H IL-2 mRNA.
- Transcription Factor mRNA: c-Myc, H Sox2, Nanog, KLF4, LIN28 and OCT4 mRNA.
Self-amplifying RNA (saRNAs)
OZ Biosciences also offers self-amplifying RNA (saRNAs) that are designed to produce high expression level of protein with enhanced length of duration. These saRNAs are stabilized with 5’ Cap 1 structure and 3’ poly(A) tail. They can be modified with 5-methyl-Cytidine (m5C) or unmodified.
Categories of ready-to-use saRNAs:
Custom mRNA/saRNA Synthesis Service
With over 15 years of nucleic acid delivery expertise, OZ Biosciences is confident in providing you with the best-in-class service for the production of high quality mRNAs & saRNAs.
We are able to synthesis custom messenger RNA (mRNAs) and self-amplifying RNA (saRNAs) at microgram to multigram scales, from a few hundred up to several thousand bases, with a wide variety of modifications including 5’ terminal modifications with cap, internal modification such as 5-methoxyuridine (other modified nucleotides are available) and 3’ modification such as poly-A tail. Fluorescent labeling with Cy5, Cy3 or other options is available.
Production Process
The mRNA production process at OZ Biosciences has been meticulously perfected over the years to achieve an exceptional level of optimization. Using state-of-the-art enzymes, considered to be the most efficient available, the process guarantees production that minimizes dsRNA formation. This attention to detail results in mRNAs of the highest quality, reflecting an ongoing commitment to excellence and innovation in the field.
Quality control
We do know that the reproducibility of scientific experiments is very important to researchers. That is why we developed a quality control system tailored to each product, enabling us to detect defective batches immediately.
Our mRNAs & saRNAs, whether custom or catalog, undergo standard quality control, including measurement of size, integrity and purity by fragment analyzer, agarose gel and Nanodrop (concentration 260/280 and 260/230), a sterility test and an experimental validation (transfection / expression).
However, we have developed additional tests to extend the analysis to include endotoxin detection and double strand RNA (dsRNA) quantification.
|
Items |
Specification |
| Appearance | Clear |
| Integrity | One peak, right size |
| One peak, right size | |
| Concentration | 1mg/ml +/- 5% |
| Purity (A260/280) | >1,8 for Unmod , >1,7 for modified |
| Sterility | Absence of growth after 14 days |
| Fonctionality | Protein expression after transfection |
| Endotoxin | (≤ 0.5 EU/mL) |
| dsRNA | <0.05% |
| Fluorophore concentration | >/= 10pmol/µl |
Example of Quality Control results :
Agarose gel
Capillary electrophoresis
Endotoxin content
dsRNA content
New enzyme for low dsRNA in our mRNAs!
As part of our continuous quality improvement, we have selected a new generation of RNA polymerase that reduces dsRNA during IVT. We are able to reduce the amount of dsRNA in our catalog and in our customized mRNAs by up to 88%.
Our new quality control limit is 0.05% of dsRNA.
Comparison of dsRNA amount in different mRNA produced by OZ Biosciences before and after the production process improvement.
